85 related articles for article (PubMed ID: 9428788)
1. Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation.
Qian X; O'Rourke DM; Drebin J; Zhao H; Wang Q; Greene MI
DNA Cell Biol; 1997 Dec; 16(12):1395-405. PubMed ID: 9428788
[TBL] [Abstract][Full Text] [Related]
2. Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential.
Zhang HT; O'Rourke DM; Zhao H; Murali R; Mikami Y; Davis JG; Greene MI; Qian X
Oncogene; 1998 Jun; 16(22):2835-42. PubMed ID: 9671404
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly.
O'Rourke DM; Nute EJ; Davis JG; Wu C; Lee A; Murali R; Zhang HT; Qian X; Kao CC; Greene MI
Oncogene; 1998 Mar; 16(9):1197-207. PubMed ID: 9528862
[TBL] [Abstract][Full Text] [Related]
4. Demonstration by two-color flow cytometry that tyrosine kinase activity is required for down-modulation of the oncogenic neu receptor.
Brown VI; Shah N; Smith R; Hellman M; Jarett L; Mikami Y; Cohen E; Qian X; Greene MI
DNA Cell Biol; 1994 Feb; 13(2):193-209. PubMed ID: 7910024
[TBL] [Abstract][Full Text] [Related]
5. Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting.
Jaramillo ML; Leon Z; Grothe S; Paul-Roc B; Abulrob A; O'Connor McCourt M
Exp Cell Res; 2006 Sep; 312(15):2778-90. PubMed ID: 16806168
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
Ye D; Mendelsohn J; Fan Z
Oncogene; 1999 Jan; 18(3):731-8. PubMed ID: 9989823
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein.
Qian X; O'Rourke DM; Zhao H; Greene MI
Oncogene; 1996 Nov; 13(10):2149-57. PubMed ID: 8950982
[TBL] [Abstract][Full Text] [Related]
8. The carboxyl terminus of epidermal growth factor receptor/erbB-2 chimerae is internalization impaired.
Sorkin A; Di Fiore PP; Carpenter G
Oncogene; 1993 Nov; 8(11):3021-8. PubMed ID: 8105439
[TBL] [Abstract][Full Text] [Related]
9. Biological studies and potential therapeutic applications of monoclonal antibodies and small molecules reactive with the neu/c-erbB-2 protein.
Dougall WC; Greene MI
Cell Biophys; 1994; 24-25():209-18. PubMed ID: 7736525
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic activation of the PDGF beta receptor by the transmembrane domain of p185neu*.
Petti LM; Irusta PM; DiMaio D
Oncogene; 1998 Feb; 16(7):843-51. PubMed ID: 9484775
[TBL] [Abstract][Full Text] [Related]
11. Roles for a cytoplasmic tyrosine and tyrosine kinase activity in the interactions of Neu receptors with coated pits.
Gilboa L; Ben-Levy R; Yarden Y; Henis YI
J Biol Chem; 1995 Mar; 270(13):7061-7. PubMed ID: 7706244
[TBL] [Abstract][Full Text] [Related]
12. Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation.
Qian X; Dougall WC; Hellman ME; Greene MI
Oncogene; 1994 May; 9(5):1507-14. PubMed ID: 7908733
[TBL] [Abstract][Full Text] [Related]
13. Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active.
Yarden Y
Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2569-73. PubMed ID: 1969636
[TBL] [Abstract][Full Text] [Related]
14. The role of the neu oncogene product in cell transformation and normal development.
Kokai Y; Wada T; Myers JN; Brown VI; Dobashi K; Cohen J; Hamuro J; Weiner DB; Greene MI
Princess Takamatsu Symp; 1988; 19():45-57. PubMed ID: 2908355
[TBL] [Abstract][Full Text] [Related]
15. Identification of EGF receptor C-terminal sequences 1005-1017 and di-leucine motif 1010LL1011 as essential in EGF receptor endocytosis.
Wang Q; Zhu F; Wang Z
Exp Cell Res; 2007 Sep; 313(15):3349-63. PubMed ID: 17643422
[TBL] [Abstract][Full Text] [Related]
16. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
18. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y
Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426
[TBL] [Abstract][Full Text] [Related]
19. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
20. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
